News
Univercells Technologies introduces the NevoLine Upstream Platform
Univercells Technologies is introducing the new generation of the NevoLine biomanufacturing product family, the NevoLine Upstream platform.
This high-performance, low-footprint upstream manufacturing platform is suitable for multiple viral applications to support the booming gene therapy market and offer a cost-effective...
Clinical Trials
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trial of STI-1499 Neutralizing Antibody in COVID-19 Positive Patients
Sorrento Therapeutics, Inc. announced that it received a study may proceed letter from the FDA for its phase 1 clinical trial for COVI-GUARD (STI-1499) in hospitalized COVID-19 patients.
As Sorrento previously announced, in preclinical studies, STI-1499 demonstrated 100% in vitro...
Drug Research
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
Seattle Genetics, Inc. and Merck, known as MSD outside the United States and Canada, announced two new strategic oncology collaborations.
The companies will globally develop and commercialize Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody-drug conjugate (ADC) targeting LIV-1, which is...
News
CPhI Annual Report 2020 Part 1: 2025 will see cell and gene therapy capacity shortages in the USA and 10+ mAb approvals in China
CPhI Annual Report – launched ahead of the first CPhI Festival of Pharma (5-16 October, 2020), the world’s largest digital pharma Expo – predicts dramatic growth of new mAb production in China, capacity shortages for cell and gene therapies...
News
Gilead Sciences to acquire ADC developer Immunomedics for $21bn
Gilead Sciences, Inc. and Immunomedics announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously...
News
Oxford University resume Covid-19 vaccine trial
Oxford University on Saturday, 13th Sep. 2020 announced resuming coronavirus vaccine trials, the study which was suspended following a reported side-effect in a UK patient. Oxford University, developing this vaccine with pharmaceutical company AstraZeneca confirmed the restart across all...
News
DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India
India's top drug regulator-- Drugs Controller General of India (DCGI) has granted permission to Serum Institute of India (SII) to conduct phase 2 and 3 human clinical trials in India on the potential covid-19 vaccine, a senior government official...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















